BioLargo Statistics
Total Valuation
BioLargo has a market cap or net worth of 49.35 million. The enterprise value is 46.85 million.
| Market Cap | 49.35M |
| Enterprise Value | 46.85M |
Important Dates
The next estimated earnings date is Friday, November 14, 2025.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BioLargo has 310.89 million shares outstanding. The number of shares has increased by 3.19% in one year.
| Current Share Class | 310.89M |
| Shares Outstanding | 310.89M |
| Shares Change (YoY) | +3.19% |
| Shares Change (QoQ) | +0.64% |
| Owned by Insiders (%) | 6.04% |
| Owned by Institutions (%) | 0.04% |
| Float | 268.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.51 |
| PB Ratio | 8.14 |
| P/TBV Ratio | 5.64 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -12.02 |
| EV / Sales | 3.33 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -6.25 |
Financial Position
The company has a current ratio of 2.25, with a Debt / Equity ratio of 0.61.
| Current Ratio | 2.25 |
| Quick Ratio | 1.28 |
| Debt / Equity | 0.61 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.49 |
| Interest Coverage | -38.67 |
Financial Efficiency
Return on equity (ROE) is -110.36% and return on invested capital (ROIC) is -46.16%.
| Return on Equity (ROE) | -110.36% |
| Return on Assets (ROA) | -35.15% |
| Return on Invested Capital (ROIC) | -46.16% |
| Return on Capital Employed (ROCE) | -75.33% |
| Revenue Per Employee | 334,571 |
| Profits Per Employee | -92,810 |
| Employee Count | 44 |
| Asset Turnover | 1.25 |
| Inventory Turnover | 24.75 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.45% in the last 52 weeks. The beta is -0.24, so BioLargo's price volatility has been lower than the market average.
| Beta (5Y) | -0.24 |
| 52-Week Price Change | -25.45% |
| 50-Day Moving Average | 0.19 |
| 200-Day Moving Average | 0.22 |
| Relative Strength Index (RSI) | 41.07 |
| Average Volume (20 Days) | 433,919 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.30 |
Income Statement
In the last 12 months, BioLargo had revenue of 14.05 million and -3.90 million in losses. Loss per share was -0.01.
| Revenue | 14.05M |
| Gross Profit | 6.38M |
| Operating Income | -6.34M |
| Pretax Income | -6.60M |
| Net Income | -3.90M |
| EBITDA | -6.18M |
| EBIT | -6.34M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 3.47 million in cash and 3.67 million in debt, giving a net cash position of -197,000 or -0.00 per share.
| Cash & Cash Equivalents | 3.47M |
| Total Debt | 3.67M |
| Net Cash | -197,000 |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | 6.06M |
| Book Value Per Share | 0.03 |
| Working Capital | 5.11M |
Cash Flow
In the last 12 months, operating cash flow was -7.48 million and capital expenditures -14,000, giving a free cash flow of -7.50 million.
| Operating Cash Flow | -7.48M |
| Capital Expenditures | -14,000 |
| Free Cash Flow | -7.50M |
| FCF Per Share | -0.02 |
Margins
Gross margin is 45.40%, with operating and profit margins of -45.13% and -27.74%.
| Gross Margin | 45.40% |
| Operating Margin | -45.13% |
| Pretax Margin | -46.93% |
| Profit Margin | -27.74% |
| EBITDA Margin | -43.99% |
| EBIT Margin | -45.13% |
| FCF Margin | n/a |
Dividends & Yields
BioLargo does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.19% |
| Shareholder Yield | -3.19% |
| Earnings Yield | -7.90% |
| FCF Yield | -15.19% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioLargo has an Altman Z-Score of -10.41. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.41 |
| Piotroski F-Score | n/a |